β-catenin/CBP-IN-1
Modify Date: 2024-01-09 14:39:46
β-catenin/CBP-IN-1 structure
|
Common Name | β-catenin/CBP-IN-1 | ||
|---|---|---|---|---|
| CAS Number | 1198780-38-9 | Molecular Weight | 658.64 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C33H35N6O7P | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of β-catenin/CBP-IN-1β-catenin/CBP-IN-1 (CBP/β-catenin inhibitor) is a potent and selective CBP/β-catenin inhibitor, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus[1]. |
| Name | β-catenin/CBP-IN-1 |
|---|
| Description | β-catenin/CBP-IN-1 (CBP/β-catenin inhibitor) is a potent and selective CBP/β-catenin inhibitor, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus[1]. |
|---|---|
| Related Catalog | |
| Target |
Wnt |
| In Vivo | β-catenin/CBP-IN-1 (intraperitoneal injection;1mg/kg; 42 days) has a treatment effect on liver fibrosis in hepatic fibrosis Cre/loxP/HCV-MxCreTg mouse model[1]. |
| References |
[1]. Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1. |
| Molecular Formula | C33H35N6O7P |
|---|---|
| Molecular Weight | 658.64 |